1. WuXi AppTec implements its first interim dividend plan, paying RMB1.03 billion. 2. Total cash dividends distributed this year reach RMB4.88 billion. 3. Cash dividends and share buybacks represent over 70% of net profit for 2024. 4. Pursuing strategies to enhance shareholder value and support growth. 5. The company supports R&D in pharmaceutical industries across various regions.
WuXi AppTec's significant dividend payout reflects strong financial health and shareholder value focus. Historically, companies demonstrating consistent dividend increases often see positive stock performance due to increased investor confidence.
The announcement directly influences investor perceptions of WuXi AppTec's financial health. A strong commitment to shareholder returns through dividends can significantly impact stock price and market perception.
The immediate impact of the dividend announcement is likely to boost investor sentiment. Short-term stock prices often respond positively to such announcements, though long-term effects depend on sustained performance.
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.
So far this year, to enhance shareholder value, WuXi AppTec has distributed a total of RMB4.88 billion in cash dividends to investors through its annual dividend, special dividend and interim dividend. The Company's cash dividends, combined with share repurchases and cancellations implemented this year, total RMB6.88 billion, representing over 70% of the net profit attributable to the owners of the Company in 2024.
For A-share shareholders, please refer to the Company's announcement HERE.
For H‑share shareholders, please refer to the Company's announcement HERE.
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.
View original content:https://www.prnewswire.com/news-releases/wuxi-apptec-implements-its-first-interim-dividend-plan-distributing-rmb1-03-billion-in-cash-dividends-302562337.html
SOURCE WuXi AppTec